Virtus Investment Advisers’s BioMarin Pharmaceuticals BMRN Stock Holding History

Virtus Investment Advisers’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.19M	Buy	20,784 +4,948	+31%	+$271K	0.28%	180
2026 Q1	$895K	Buy	15,836 +3,018	+24%	+$176K	0.25%	148
2025 Q4	$762K	Buy	12,818 +5,060	+65%	+$275K	0.21%	148
2025 Q3	$420K	Hold	7,758	–	–	0.12%	222
2025 Q2	$426K	Buy	7,758 +2,342	+43%	+$138K	0.14%	215
2025 Q1	$383K	Buy	+5,416	New	+$364K	0.1%	213

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Virtus Investment Advisers's BMRN Position: Q2 2026 in Review

Virtus Investment Advisers increased its BioMarin Pharmaceuticals (BMRN) stake by 31% in Q2 2026, buying an estimated $271K and bringing the position to 20,784 shares worth $1.19M. The position accounts for 0.28% of the portfolio, ranked #180.

Virtus Investment Advisers first reported a position in BMRN in Q1 2025 and has held it in 6 quarters since. 562 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Virtus Investment Advisers held 20,784 shares of BioMarin Pharmaceuticals worth $1.19M as of Q2 2026.
Virtus Investment Advisers bought 4,948 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $271K.
BioMarin Pharmaceuticals made up 0.28% of Virtus Investment Advisers's portfolio in Q2 2026, its #180 holding.
Virtus Investment Advisers first reported a position in BioMarin Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
562 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.